Dr. Aaron Gerds interviews Dr. Martin Dreyling to discuss his abstract on the efficacy and safety of first-line treatment with ibrutinib compared to immunochemotherapy plus autologous transplant in mantle cell lymphoma (MCL), the results of which were presented at the 64th ASH Annual Meeting and Exposition in New Orleans, Louisiana.

свернуть